Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN SULFATE versus KANAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN SULFATE versus KANAMYCIN SULFATE.
GENTAMICIN SULFATE vs KANAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic